Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NT5E | P21589 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 10/20 | 0.42 |
| ▸ | CA1 | P00915 | 5/20 | 0.42 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA9 | Q16790 | 4/20 | 0.42 |
| ▸ | CA4 | P22748 | 3/20 | 0.42 |
| ▸ | CA6 | P23280 | 3/20 | 0.42 |
| ▸ | CA5A | P35218 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.38 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6688445 | 0.98 | LMNA (0.45) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL7088221 | 0.88 | CA2 (0.46) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL8533059 | 0.86 | CA2 (0.47) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL6704699 | 0.85 | CA2 (0.46) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL11583429 | 0.84 | LMNA (0.56) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL6704622 | 0.83 | CA2 (0.47) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL30446884 | 0.80 | CA2 (0.57) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL92261 | 0.78 | CA2 (0.67) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL1804175 | 0.78 | LMNA (0.50) | LMNATSHRALDH1A1NT5ESMN1; SMN2 | |
| SCHEMBL16350024 | 0.78 | LMNA (0.50) | LMNATSHRALDH1A1NT5ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-08-14 | — | — | US | disclosed |
| EP-0820312-B1 | TERNARY RADIOPHARMACEUTICAL COMPLEXES | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-1195168-A2 | Ternary radiopharmaceutical complexes | Dupont Pharmaceuticals Company (US) | 2002-04-10 | — | — | EP | disclosed |
| US-6010679-A | TRANSITION METAL RADIONUCLEOLIDE; CONTRAST AGENTS FOR DIAGNOSING CARDIOVASCULAR DISORDERS, CANCER | LANTHEUS MEDICAL IMAGING, INC. | 2000-01-04 | — | — | US | disclosed |
| EP-0789551-A4 | HAIR CARE PERMING AGENTS AND PROCESSES | LAU JOHN R (US) | 1998-12-02 | — | — | EP | disclosed |
| US-5744120-A | PHOSPHINE OR ARSINE LIGATED TECHNETIUM-99M LABELED HYDRAZINO OR DIAZINO MODIFIED BIOLOGICALLY ACTIVE MOLECULES THAT SELECTIVELY LOCALIZE AT SITES OF DISEASE | THE DUPONT MERICK PHARMACEUTICAL COMPANY (US) | 1998-04-28 | — | — | US | disclosed |
| EP-0820312-A4 | TERNARY RADIOPHARMACEUTICAL COMPLEXES | DU PONT MERCK PHARMA (US) | 1998-03-18 | — | — | EP | disclosed |
| EP-0820312-A1 | TERNARY RADIOPHARMACEUTICAL COMPLEXES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-28 | — | — | EP | disclosed |
| EP-0789551-A1 | HAIR CARE PERMING AGENTS AND PROCESSES | LAU, John R. (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997011672-A1 | HAIR CARE PERMING AGENTS AND PROCESSES | LAU JOHN R (US) | 1997-04-03 | — | — | WO | disclosed |
| WO-1996031243-A1 | TERNARY RADIOPHARMACEUTICAL COMPLEXES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030152512-A1 | Imaging thrombus with glycoprotein llb/llla antagonists | FGB, SELPLG, SELL | LMNA 1619/4885TSHR 279/4885ALDH1A1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.